Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2024 Earnings Conference Call May 9, 2024 8:30 AM ET
Company Participants
Dr. Christopher Missling - President and CEO
Sandra Boenisch - Principal Financial Officer
Conference Call Participants
Soumit Roy - Jones Research
Ram Selvaraju - H.C. Wainwright
Tom Bishop - BI Research
Operator
Good morning. And welcome to the Anavex Life Sciences Fiscal 2024 Second Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today’s call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session, and during this session if you would like to ask a question use the Q&A box or raise your hand. Please note this conference is being recorded. The call will be available for replay on Anavex’s website at www.anavex.com.
With us today is Dr. Christopher Missling, President and Chief Executive Officer; and Sandra Boenisch, Principal Financial Officer.
Before we begin please note that during this conference call the company will make some projections and forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties.
We encourage you to review the company’s filings with the SEC. This includes without limitation the company’s Forms 10-K and 10-Q which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements.
These factors may include without limitation risks inherent in the development and or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights.
And with that, I would like to turn the call over to Dr. Missling.
Dr. Christopher Missling
Thank you, Clint, and good morning, everyone. Thank you for being with us today to review our most recently reported financial results and to provide our quarterly business update. We’re encouraged by the very recently issued FDA guidance for early Alzheimer’s disease which states that one cognitive measure alone like ADAS-Cog could be a sufficient primary endpoint for early Alzheimer’s disease.
We appreciate this new guidance and believe this opens another possible pathway for us to move forward in parallel to the initiated process of market authorization application to the European Medicine Agency, EMA, for blarcamesine for the treatment of Alzheimer’s disease which is already underway.
Full data from the blarcamesine study in Alzheimer’s disease Phase 2b/3 placebo-controlled clinical trial will be published in an upcoming peer-reviewed journal, as well analysis of RNA sequencing of the trial is underway and interim data is expected by mid-2024. Concurrently, the ATTENTION-AD open-label extension trial is ongoing and we expect to be able to share interim data in the second half of 2024.